| ||||||||||||||
|
|
|||||||||||||
Received from the Department of Anesthesiology, University of Virginia Medical Center, Charlottesville, Virginia 22908.
Abstract
A new partial agonist–antagonist analgesic drug, dezocine, was evaluated in rats for its anesthetic potency using a MAC-reduction model. Respiratory effects as shown by changes in PaCO2 were also analyzed. A reduction of approximately 50% in cyclopropane MAC was found with doses of 6 mg/kg or more. This is the largest reduction for any drug of this class. PaCO2 levels increased up to 52 mm Hg with doses of dezocine up to 2 mg/kg. No evidence of reversal of respiratory depression or of further respiratory depression was found with increasing dosages. Combining dezocine with morphine resulted in a further reduction in cyclopropane MAC without a significant change in PaCO2. This suggests that dezocine acts primarily on the same receptor (mu) as morphine and that this receptor activity is further modulated by effects of dezocine on a second opioid receptor.
Key Words: ANALGESICS: dezocine
This article has been cited by other articles:
![]() |
M. J. Picker Discriminative Stimulus Effects of the Mixed-Opioid Agonist/Antagonist Dezocine: Cross-Substitution by Mu and Delta Opioid Agonists J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1009 - 1017. [Abstract] [Full Text] |
||||
|